Cost-utility analysis of R-CHOP vs CHOP in patients with non-hodgkin's lymphoma: a systematic review

Background: Non-Hodgkin Lymphoma (NHL) ranks 11th in cancer incidence and mortality in the Philippines with the combination chemotherapy composed of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) being commonly used as treatment. However, the addition of Rituximab to CHOP (R-CHOP)...

Descrición completa

Detalles Bibliográficos
Autor Principal:	Cadag, Camille Francesca T. (Author)
Outros autores:	Lorenzo, Althea B. (author .), Mercado, Justine Marie M. (author .), Ngo, Frances Lois U. (adviser .)
Formato:	Thesis
Idioma:	English
Subjects:	Cost effectiveness > Lymphoma--therapy > Comparative effectiveness research. Non-Hodgkin’s Lymphoma, . R-CHOP. CHOP. Rituximab. Cost-utility. Economic evaluation.